Hoth Therapeutics, Inc. (HOTH) Wednesday reported positive results from the preclinical study of its lead drug candidate HT-ALZ for the treatment of Alzheimer's disease.
HT-ALZ has shown significant cognitive and behavioral benefits in APP/PS1 mouse models of Alzheimer's disease. The study demonstrated that chronic oral administration of HT-ALZ led to marked improvement in memory, reduction of anxiety-like behavior, and enhanced sensorimotor gating, all without impairing motor function. Additionally, treatment with HT-ALZ led to a rapid 15 percent reduction in brain interstitial fluid Aß levels.
The company plans to advance HT-ALZ into clinical development.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.